N/A N=185 Pivotal Study to Assess the Safety and Effectiveness of the iTind Device
Benign Prostate Hyperplasia
Primary: Month 3 Results in the IPSS Score in Both Arms. — 12.57; 15.8 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Powered Hip Exoskeleton Assistance Study
Lower Limb Injury
Primary: Self-Selected Walking Speed Using Hip Exoskeleton Assistance Across Different Locomotion Modes — 1.14; 1.26; 1.26; 0.61 meters per second — p=0.9547
Phase 2 N=19 Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Melanoma
Primary: Median Overall Survival Response to Abraxane Plus Ipilimumab Therapy — 24.9 months
Phase 1 N=10 Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
Lung Cancer
Primary: Confirmation of Tumor Targeting as Measured by the Number of Patients With Assessable Lesions Greater Than or Equal to 2 cm Measured by FDG-PET and SPECT Imaging. — 5; 5…
Phase 3 N=25 Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction
Smoking Cessation · Harm Reduction
Primary: Number of Participant Reporting Continuous Complete Switching From Cigarettes to Halo G6 — 8 Participants
Phase 1 N=24 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of Maribavir — 15.8; 17.4; 9.03; 26.3 Micrograms per milliliter (mcg/mL)
Phase 2 N=58 A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
Psoriasis
Primary: Change in Target Lesion Individual Component Scores for Erythema, Scaling and Thickness Compared to Baseline — -0.5; -0.5; -0.8; -1.0 Scores on a scale
Phase 2 N=261 A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye
Dry Eye Syndrome
Primary: Change From Baseline in Schirmer I Test (Without Anesthesia) vs Week 4 - Full Analysis Set — 2.60; 3.99; 1.68 mm — p=0.078
Phase 2 N=24 A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Lung Adenocarcinoma · Lung Cancer · Lung Cancer Metastatic
Primary: Participants Response Rate — 11; 4; 8; 1 participants
Phase 4 N=10 Fenofibrate in Type 2 Diabetes
Diabetes Mellitus, Type II
Primary: Number of Individual Plasma Proteins That Changed From Baseline to End-point Based on Limma T-Test of Protein Abundance as Determined by Proteomic Analysis Via Liquid…
Phase 3 N=628 A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -0.63; -0.56 Percentage of HbA1c — p=0.321
Phase 1 N=91 Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine
COVID-19
Primary: Occurrence of Solicited Local AE Signs and Symptoms 7 Days Following the Vaccination — 10; 12; 10; 2 Participants
Phase 3 N=2,100 Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older
Influenza Immunization · Healthy Volunteers
Primary: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28 — 309.0; 110.0; 540.0; 239.9 titers
Phase 2 N=26 Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
N/A N=27 RehabTouch Home Therapy for Stroke Patients
Cerebral Stroke
Primary: Change in Fugl-Meyer Arm Motor Score From Baseline to One Month Post Therapy — 8.0; 3.1 Score on a Scale — p=0.03